369 related articles for article (PubMed ID: 23259453)
1. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
TrehanPati N; Kotillil S; Hissar SS; Shrivastava S; Khanam A; Sukriti S; Mishra SK; Sarin SK
J Clin Immunol; 2011 Jun; 31(3):509-20. PubMed ID: 21305387
[TBL] [Abstract][Full Text] [Related]
3. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
4. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Gilson RJ; Chopra KB; Newell AM; Murray-Lyon IM; Nelson MR; Rice SJ; Tedder RS; Toole J; Jaffe HS; Weller IV
J Viral Hepat; 1999 Sep; 6(5):387-95. PubMed ID: 10607255
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
[TBL] [Abstract][Full Text] [Related]
7. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Nan XP; Zhang Y; Yu HT; Sun RL; Peng MJ; Li Y; Su WJ; Lian JQ; Wang JP; Bai XF
Viral Immunol; 2012 Feb; 25(1):21-8. PubMed ID: 22233255
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
Arasli M; Ustundag Y; Delikanli B; Harmandar F; Buyukuysal C
Hepatogastroenterology; 2012 May; 59(115):851-7. PubMed ID: 22193343
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.
Cooksley H; Chokshi S; Maayan Y; Wedemeyer H; Andreone P; Gilson R; Warnes T; Paganin S; Zoulim F; Frederick D; Neumann AU; Brosgart CL; Naoumov NV
Antimicrob Agents Chemother; 2008 Jan; 52(1):312-20. PubMed ID: 17984230
[TBL] [Abstract][Full Text] [Related]
11. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
Zhang L; Wang Q; Zhao P; Hu X; Jiang Y
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):514-23. PubMed ID: 24773272
[TBL] [Abstract][Full Text] [Related]
12.
Sung PS; Park DJ; Kim JH; Han JW; Lee EB; Lee GW; Nam HC; Jang JW; Bae SH; Choi JY; Shin EC; Park SH; Yoon SK
Front Immunol; 2019; 10():1319. PubMed ID: 31244857
[TBL] [Abstract][Full Text] [Related]
13. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
14. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.
Peng G; Li S; Wu W; Tan X; Chen Y; Chen Z
Mol Immunol; 2008 Feb; 45(4):963-70. PubMed ID: 17868872
[TBL] [Abstract][Full Text] [Related]
15. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B;
Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN
PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734
[TBL] [Abstract][Full Text] [Related]
19. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
20. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
